ArticleCureus2025
Erythema Induratum (Nodular Vasculitis) of the Lower Extremities Without Tuberculosis in Psoriasis on Secukinumab (Interleukin 17A Inhibition): A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erythema induratum/nodular vasculitis (EI/NV) classically associates with tuberculosis (TB), yet TB-negative disease is increasingly recognized in low-prevalence settings. A 58-year-old nurse with palmoplantar psoriasis controlled on secukinumab developed 6-8 months of exquisitely tender, ulcerating lower-leg nodules refractory to multiple antibiotics. Cultures were largely unrevealing; TB testing and broad microbial cell-free DNA were negative. Incisional biopsies showed lobular panniculitis with mixed inflammation and focal vasculitis, consistent with EI/NV; special stains/PCR for mycobacteria were negative. Multidisciplinary management included brief targeted Gram-positive coverage, high-dose prednisone taper, temporary cessation of IL-17 blockade, and transition to colchicine for steroid-sparing control. Within weeks, no new lesions appeared, and prior ulcers healed. This case underscores the importance of clinicopathologic correlation, rigorous infectious exclusion, and coordinated dermatology - infectious diseases - rheumatology care, favoring individualized anti-inflammatory therapy over empiric antituberculous treatment when TB risk is low and diagnostics are negative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.